Navigation Links
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Date:8/19/2007

l benefit response (CBR), time to progression (TTP), duration of response (DOR), progression-free survival, and best ORR throughout the study. Patients enrolled in the trial will receive carfilzomib twice weekly for three weeks every 28 days.

"Based on promising laboratory and clinical data, we believe that carfilzomib holds promise in treating patients with multiple myeloma, including those for whom other treatments have failed," said Sundar Jagannath, M.D., Saint Vincent's Comprehensive Cancer Center, where the first patient was enrolled. "We are excited to bring this compound into the MMRC as a critical step in bringing this new treatment to patients."

In the coming weeks, the MMRC and Proteolix will also begin enrolling an open-label, single-arm, Phase 2 study of carfilzomib in patients with relapsed multiple myeloma, who will be stratified by bortezomib (Velcade(R), Millennium Pharmaceuticals, Inc.) history.

About Carfilzomib

Carfilzomib is a structurally- and mechanistically-novel proteasome inhibitor that exhibits a high level of selectivity for the unique N-terminal threonine active sites within the proteasome. Carfilzomib is similar to bortezomib in that it is a potent inhibitor of the proteasome chymotrypsin- like activity, but unlike bortezomib, carfilzomib has shown minimal cross- reactivity with the other catalytic sites within the proteasome or across other protease classes. Phase 1 clinical studies confirmed that patients who have relapsed or progressed following multiple therapies can still achieve durable anti-tumor responses with carfilzomib. In addition to the two Phase 2 single-agent trials in myeloma and ongoing studies in lymphoma, a clinical trial in solid tumors and a trial exploring carfilzomib in combination with an FDA-approved agent will be initiated by the end of the year.

"The Phase 1 data consistently demonstrate carfilzomib anti-tumor activity in myeloma patients who have failed multiple lines of therapy,
'/>"/>

SOURCE Proteolix

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 Johnson & Johnson (NYSE: JNJ ... third party to review requests made to the Janssen ... for compassionate use of its investigational medicines. This new ... a single Janssen investigational medicine and, if successful, will ... across Johnson & Johnson. In keeping with ...
(Date:5/6/2015)... , May 6, 2015  Zimmer Holdings, Inc. (NYSE and ... that it will be presenting at the Bank of America ... hotel in Las Vegas, Nevada on ... A live webcast of the presentation can be accessed ... webcast will be archived for replay following the conference. ...
(Date:5/6/2015)... 6, 2015  The fairness of the proposed acquisition ... Alexion Pharmaceuticals, Inc. ("Alexion") is being investigated by WeissLaw ... for possible breaches of fiduciary duty and other violations ... for agreeing to sell the Company to Alexion.  On ... for Alexion to acquire GEVA in a transaction valued ...
Breaking Medicine Technology:Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 2Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 3Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 4Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 5WeissLaw LLP Investigates the Synageva Biopharma Corp. Acquisition 2
... Radient Pharmaceuticals Corporation (OTCQX: RXPC.PK - News ... developer and marketer of cancer tests, today announces it ... in Taipei, Taiwan. Previously, Radient,s agreement with ... Radient,s flagship product Onko-Sure® cancer test in Taiwan.  Radient ...
... Dec. 21, 2011  Shareholders of Medco Health Solutions, Inc. (NYSE: ... Express Scripts. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO ) ... vote present in person or by proxy at a special ... Merger dated July 20, 2011 by a margin of 99 ...
Cached Medicine Technology:Radient Pharmaceuticals Corporation Expands Distribution of Onko-Sure® in Asia; Receives Payment on First Order of 60 Kits 2Radient Pharmaceuticals Corporation Expands Distribution of Onko-Sure® in Asia; Receives Payment on First Order of 60 Kits 3Medco Shareholders Approve Merger With Express Scripts 2
(Date:5/6/2015)... MJNational LLC strengthens its consultant agreement ... Bizcard ™ platform. This exciting new SMS platform creates ... Sales / Services. Now you can reach out ... products, services and ticker symbol through an easy to ... LLC will provide managed support and services to advance ...
(Date:5/6/2015)... Sulphur Springs, Texas (PRWEB) May 06, 2015 ... the stages of the HIMSS EMR Adoption Model, ... remove paper, improve patient engagement and automate processes. ... had transitioned from paper-driven to electronic workflows, patient ... to hard copies of consents. With HIMSS Stage ...
(Date:5/6/2015)... Qushanna Doby (20) was arrested for child neglect, ... in Florida while under the influence of Flakka, according to ... released by CBS4’s Peter D’Oench records Doby distraught in a ... around one year old. The drug treatment center in Florida ... named. The residents polled by CBS Miami express concern about ...
(Date:5/6/2015)... Va. (PRWEB) May 06, 2015 ... in the state of Virginia to acquire Intuitive ... surgical robot. The system upgrade includes enhanced surgical ... minimally invasive procedures across a wide spectrum of ... options, reduced pain and quicker recovery times. , ...
(Date:5/6/2015)... Baptist Medical Center Jacksonville and the ... Florida and southeast Georgia region offering MAKOplasty® Hip ... total hip replacement surgery performed using the RIO® ... enables the accurate alignment and positioning of implants. ... partial knee resurfacing using the RIO system since ...
Breaking Medicine News(10 mins):Health News:Cannabiz Mobile Inc. Launches the Canna Bizcard ™ Platform to Support to Cannabis Market 2Health News:Cannabiz Mobile Inc. Launches the Canna Bizcard ™ Platform to Support to Cannabis Market 3Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 2Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 3Health News:Flakka Induced Mother Abandons Baby, found by Florida Drug Treatment Center; New Video Released 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 2Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 3Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 4
... researchers report 80 percent success with their method, , ... that they,ve developed ways to detect 80 percent of ... more than one in 10 women who give birth. ... would make it possible to intervene to prevent it ...
... FAIRFAX, Va.The Society of Interventional Radiology Foundation recently ... a future scholarship fund for interventional radiology fellows ... dedicated to advancing the clinical needs of interventional ... conducting pivotal basic and clinical trials research. ...
... 2009 Late-breaking data from SPIRIT IV, a large-scale ... shows that an everolimus-eluting stent demonstrated enhanced safety and ... artery lesions when compared to a paclitaxel-eluting stent, and ... drug-eluting stents without sacrificing safety. Unlike similar ...
... conducted by Dr. Eric Blough and his colleagues at ... pain reliever acetaminophen may help prevent age-associated muscle loss ... may affect the regulation of protein kinase B (Akt), ... regulation of cellular survival, proliferation and metabolism. The ...
... influenza could slow growth in key industries and stall already-weak ... says a health economist in the University of Alabama at ... vitally important sectors in the economy of many U.S. cities ... the spread of the virus, consumers and businesses may respond ...
... ... External services for pharmaceutical firms have shown consistent growth in recent ... The global share of biotechnology services spending is in the billions ... of high-quality external services available to pharma ranges from supportive IT, ...
Cached Medicine News:Health News:Predicting Postpartum Depression May Be Possible 2Health News:Society of Interventional Radiology Foundation receives $1 million legacy gift 2Health News:SPIRIT IV trial shows everolimus stent sets new standard for event-free survival 2Health News:Research shows safe dosages of common pain reliever may help prevent conditions related to aging 2Health News:Swine flu could wreak more havoc on US economy, says UAB economist 2Health News:Cambridge Healthtech Institute and Bio-IT World Launch a New eNewsletter: Pharma Services News 2
... duet Signature Series multipurpose gamma ... FDG imaging applications. The system uniquely combines ... the features and flexibility of modern day ... unit.,The e.cam duet maximizes camera ...
In Stainless steel. Available in 1.5, 2.0,3.0 & 3.5 MM...
... AXIOM Artis FA is ... C-arm system whose flexible ... for vascular and non-vascular ... provides complete ergonomic system ...
.60 x 22mm, angled 60, .33mm end port [Simcoe]...
Medicine Products: